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Background: The p21 codon 31 single nucleotide polymorphism (SNP), rs1801270, has been linked to cervical
cancer but with controversial results. The aims of this study were to investigate the role of p21 SNP-rs1801270 and
other untested p21 SNPs in the risk of cervical cancer in a Chinese population.
Methods: We genotyped five p21 SNPs (rs762623, rs2395655, rs1801270, rs3176352, and rs1059234) using
peripheral blood DNA from 393 cervical cancer patients and 434 controls.
Results: The frequency of the rs1801270 A allele in patients (0.421) was significantly lower than that in controls
(0.494, p = 0.003). The frequency of the rs3176352 C allele in cases (0.319) was significantly lower than that in
controls (0.417, p < 0.001).The allele frequency of other three p21 SNPs showed not statistically significantly
different between patients and controls. The rs1801270 AA genotype was associated with a decreased risk for the
development of cervical cancer (OR = 0.583, 95%CI: 0.399 - 0.853, P = 0.005). We observed that the three p21 SNPs
(rs1801270, rs3176352, and rs1059234) was in linkage disequilibrium (LD) and thus haplotype analysis was
performed. The AGT haplotype (which includes the rs1801270A allele) was the most frequent haplotype among all
subjects, and both homozygosity and heterozygosity for the AGT haplotype provided a protective effect from
development of cervical cancer.
Conclusions: We show an association between the p21 SNP rs1801270A allele and a decreased risk for cervical
cancer in a population of Chinese women. The AGT haplotype formed by three p21 SNPs in LD (rs1801270,
rs3176352 and rs1059234) also provided a protective effect in development of cervical cancer in this population.
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Cervical cancer is the second most common cancer in
women worldwide [1,2]. The human papilloma virus
(HPV) appears to be a necessary factor in the develop-
ment of almost all cases (> 90%) of cervical cancer [3].
The HPV E6 and E7 proteins are viral genes expressed
in virtually all HPV-positive cervical carcinomas, and
many experiments have shown that these are cooperative
viral oncoproteins [4] that inactivate p53 and retino-
blastoma (pRb) tumor suppressors, promoting carcino-
genesis [4,5].
HPV infection is relatively common while only a small
fraction of those infected develop cancer, suggesting that
additional environmental, genetic, or immunological* Correspondence: zsl0909@sina.com
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reproduction in any medium, provided the orfactors contribute to the progression to cervical cancer
[6,7]. Cell cycle progression is regulated by cyclin-
dependent kinases, crucial for normal growth and differ-
entiation. Disruption of cell cycle control is common in
cancer cells and is believed to play an essential role in
cancer initiation and development. The cyclin-
dependent kinase inhibitor p21 (also known as WAF1or
CIP1) is encoded by the CDKN1A gene located on
chromosome 6p21.2 [8,9]. The p21 protein binds to and
inhibits the activity of cyclin-CDK2 or -CDK4 com-
plexes, and disrupts cell cycle progression at G1 phase
[10,11]. The expression of p21 is induced by the binding
of tumor suppressor protein p53 to the p21 promoter
[12-14]. The p21 protein can also interact with prolife-
rating cell nuclear antigen (PCNA), a DNA polymerase
accessory factor, and plays a regulatory role in S phase
DNA replication and DNA damage repair [15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical data of the study
group
Patients (n=393) Controls (n=434) Pa
No. (%) No. (%)
Age
≤35 82 (20.9) 105 (24.4) 0.377
36-50 219 (55.7) 241 (55.5)
>50 92 (23.4) 88 (20.3)
Smoking
Never 371 (94.4) 419 (96.5) 0.177
Ever 22 (5.6) 15 (3.5)
HPV status
HPV+ 351 (89.3) 0 (0)
HPV- 42 (10.7) 434 (100)
Clinical stageb
Stage 0 213 (54.2)
Stage I 138 (35.1)
Stage II 34 (8.7)
Stage III 7 (1.8)
Stage IV 1 (0.3)
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moter regions may adversely affect the regulation of cel-
lular proliferation and increase susceptibility to cancer.
Identification of several genetic variants in p21 have
been associated with cervical cancer [16,17]. The p21
single nucleotide polymorphism (SNP) rs1801270C/A,
which occurs in codon 31, results in an amino acid sub-
stitution of arginine for serine. This polymorphism is
located in a highly conserved region of p21 and is
expected to affect its molecular function [18]. Prior stud-
ies have linked the p21 codon 31 SNP (rs1801270) to
cervical cancer, with conflicting results [19,20]. In this
study, we genotyped five p21 SNPs (rs1801270 at codon
31, rs762623 and rs2395655 in the promoter region,
rs3176352 in an intron, and rs1059234 in the 3’ non-
coding region) in 393 cervical cancer patients and 434
cancer-free controls to look for any associations be-
tween SNP alleles or genotypes and cervical cancer in a
Chinese population.
Methods
Before beginning this study, the study protocol was
approved by the Ethics Committee of our hospital
(Shengjing Hospital of China Medical University,
Shenyang, China).
Subjects
We ascertained 393 patients with cervical cancer between
October, 2008 and September, 2011 at the Shengjing
Hospital of China Medical University. Diagnosis of cer-
vical cancer was confirmed by routine histopathological
examination. A total of 434 control samples were ran-
domly selected from the physical examination center
from the same hospital and during the same period. The
selection criteria for the controls included no individual
history of cancer, no history of cervical intraepithelial
neoplasia, normal cervical cytology and HPV examin-
ation, or normal pathological examination of the cervix
within the past two years. HPV examination was per-
formed as described previously [21]. At recruitment,
written informed consent was obtained from all study
subjects.
Age, smoking status, HPV status, and pathological
stage of all 393 cervical cancer cases and 434 controls
are presented in Table 1. The two groups seemed to be
adequately matched in terms of age and smoking.
Among the patients, 89.3% were HPV positive. The
patients’ disease severity was assessed using the FIGO
(1988) cervical cancer staging system (Table 1).
Genotype analysis
Genomic DNA was isolated from peripheral blood using
the Tiangen Blood Genome Kit. Detailed primer and re-
action information for the determination of the p21 SNPgenotypes is given in Additional file 1: Table S1. Briefly,
genotyping of rs762623 and rs2395655 was determined
by DNA sequencing (Additional file 2: Figure S1). Geno-
typing of rs1801270, rs3176352, and rs1059234 was
determined using a PCR-RFLP method. Each PCR reac-
tion consisted of 0.1 mg DNA, 1 U Taq polymerase, 10
mM Tris–HCl (pH 8.3), 50 mM KCl, 1.0 mM MgCl2, 20
mM of each dNTP, and 0.2 μM of each primer. PCR
products were digested with the indicated restriction
enzymes and visualized on agarose gels (Additional file
3: Figure S2, Additional file 4: Figure S3, Additional file
5: Figure S4).
Statistical analysis
Genotype and allele frequencies were used to assess con-
formity to Hardy–Weinberg equilibrium. Differences in
age and smoking status between patients and controls
were evaluated using the Chi-square test. The statistical
effect of this study was calculated by Gpower 14 soft-
ware (Faul & Erdfelder, Bonn, Germany). Post-hoc ana-
lysis (affect scale set to 0.2 and α set to 0.05) determined
the statistical power of this study to be 0.86. Linkage dis-
equilibrium (LD) between five loci of p21 was estimated
by the likelihood-ratio test. A Bayesian statistical method
was used to estimate the haplotypes for each subject
based on their known genotypes. These analyses were
implemented in Haploview software (version 4.2; Massa-
chusetts Institute of Technology, Cambridge, MA).
Haplotype construction and haplotype frequency ana-
lysis were performed by PHASE (version 2.1) software
Table 3 Genotype frequencies for five p21 SNPs in
cervical cancer patients and controls
Patients controls
(n=393) (n=434)
SNP No. (%) No. (%) OR (95% CI) P*
rs762623
AA 9 (2.3) 16 (3.7) 0.627 (0.272-1.447) 0.274
AG 133 (33.8) 135 (31.1) 1.096(0.816-1.472) 0.542
GG 251 (63.9) 283 (65.2) reference
rs2395655
AA 96 (24.4) 92 (21.2) 1.393 (0.936-2.074) 0.102
AG 207 (52.7) 222 (51.2) 1.245 (0.892-1.738) 0.197
GG 90 (22.9) 120 (27.6) reference
rs1801270
AA 76 (19.3) 117 (27.0) 0.583(0.399-0.853) 0.005
AC 179 (45.5) 195 (44.9) 0.811 (0.590-1.114) 0.196
CC 138 (35.1) 110 (28.1) reference
rs3176352
CC 37 (9.4) 56 (12.9) 0.637 (0.339-1.016) 0.058
CG 177 (45.0) 205 (47.2) 0.883 (0.623-1.114) 0.218
GG 179 (45.5) 173 (39.9) reference
rs1059234
CC 131 (33.3) 102 (23.5) 1.392 (0.957-2.023) 0.083
CT 160 (40.7) 221 (50.9) 0.786 (0.560-1.101) 0.161
TT 102 (26.0) 111 (25.6) reference
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SPSS 13.0 software (SPSS Inc., Chicago, USA). After
Bonferroni correction, differences were deemed signifi-
cant at p < 0.01.
Results
Association of p21 SNP alleles and genotypes with
cervical cancer risk
The frequencies of each allele of the five p21 SNPs
(rs1801270, rs762623, rs2395655, rs3176352, and
rs1059234) for patients and controls are given in Table 2.
After performing Bonferroni correction to eliminate bias
of multiple comparison, we found that the frequency of
the rs1801270 A allele in cases (0.421) was statistically sig-
nificantly lower than that found in controls (0.494; p =
0.003). Frequency of the rs3176352 C allele in cases
(0.319) was also statistically significantly lower than that
in controls (0.417; p < 0.001). The frequency of the
rs1059234 alleles between cases and controls was close to
statistical significance (p = 0.055). The frequencies of the
other two polymorphisms were not statistically significant
between the two groups (Table 2).
The genotype distributions among both patients and
controls (Table 3) were all in accordance with Hardy–
Weinberg equilibrium. We used an unconditional logis-
tic regression model adjusted for age and smoking to
find any association between genotypes and the risk of
cervical cancer (Table 3). We found that the rs1801270
AA genotype was associated with a decreased risk forTable 2 Allele frequencies for all five p21 SNPs in cervical
cancer patients and controls
Patient alleles control alleles
(n = 786) (n = 868)
SNP No. (%) No. (%) OR (95% CI) P*
rs762623
A 151 (19.2) 167 (19.2) 1.001 (0.782-1.281) 0.993
G 635 (80.8) 701 (80.8)
rs2395655
A 399 (50.8) 406(46.8) 1.139 (0.938-1.383) 0.115
G 387 (49.2) 462 (53.2)
rs1801270
A 331 (42.1) 429 (49.4) 0.744 (0.613-0.904) 0.003
C 455 (57.8) 439 (50.6)
rs3176352
C 251(31.9) 317 (41.7) 0.656 (0.533-0.807) 0.000
G 535 (68.1) 551 (58.3)
rs1059234
C 422 (53.6) 425 (48.9) 1.208 (0.996-1.466) 0.055
T 364 (46.3) 443 (51.0)
* P value was adjusted for age and smoking by multiple logistic regressions.
After Bonferroni correction, significant P value was < 0.01.
* P value was adjusted for age and smoking by multiple logistic regressions.
After Bonferroni correction, significant P value was <0.01.the development of cervical cancer (OR = 0.583, 95% CI:
0.399 - 0.853, P = 0.005). This observation is consistent
with the increased frequency of the rs1801270 A allele
among controls. However, we did not observe a similar
protective effect of the rs3176352 CC genotype even
though the rs3176352 C allele frequency was lower in
controls. No other genotypes of p21 SNPs were found to
be associated with the risk of cervical cancer (Table 3).Haplotype analysis of p21 SNPs
Linkage disequilibrium (LD) analyses gave D’ values and
r2 values (Additional file 6: Table S2), which suggested
that three of the p21 SNP loci (rs1801270, rs3176352,
and rs1059234) were in LD (Figure 1). The most com-
mon haplotypes were AGT, CCC, CGC, and CGT,
accounting for 94.1% of the haplotypes observed in all
individuals studied (Table 4). The frequency of AGT
haplotype in cases (37.88%) was slightly lower than that
in controls (44.42%), while the frequency of the CGC
and CGT haplotypes were slightly higher in cases
(20.92% and 7.07%, respectively) than in controls
(11.63% and 3.91%, respectively; Table 4).
Figure 1 Linkage disequilibrium (LD) plot and block structure of five p21 SNPs in 393 cervical cancer patients (A) and 434 cancer-free
controls (B) showing LD of three SNPs. In both groups, the haplotype block is based on confidence intervals D’. Each diamond represents the
pairwise magnitude of LD, with red indicating strong LD (D’ > 0.8) and logarithm of odds score (LOD) ≥ 2.0.
Table 5 Haplotypes of the three p21 SNPs in LD




haplotype No. (%) No. (%) OR (95% CI) P*a
ht1-AGT
ht1/ht1 67 (17.0) 87 (20.0) 0.643 (0.434-0.954) 0.028
ht1/- 166 (42.2) 215(49.5) 0.636 (0.467-0.865) 0.004
−/− 160(40.7) 132(30.4) reference
ht2- CCC
ht2/ht2 26 (6.6) 41 (9.4) 0.628 (0.368-1.072) 0.088
ht2/- 183 (46.6) 210 (48.4) 0.865 (0.650-1.151) 0.321
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the risk of cervical cancer, we looked at the frequency
distribution of the four common p21 haplotypes among
cases and controls. To further confirm the association
between the p21 haplotype and the risk of cervical can-
cer, we selected the haplotypes of which the sum fre-
quency in case and control is more than 5% and
analyzed the association between the numbers of va-
riants in each haplotype (ht1-AGT, ht2-CCC, ht3-CGC
and ht4-CGT) and the risk of cervical cancer (Table 3).
We found that homozygosity or heterozygostiy for the
AGT haplotype provides a protective effect (Table 5).
The OR value of the homozygous AGT haplotype is
0.643 (95% CI: 0.434 - 0.954, P = 0.028), while the OR
value of the heterozygous AGT haplotype is 0.636 (95%
CI: 0.467 - 0.865, P = 0.004). Homozygosity of the CGC
haplotype significantly increased the risk of cervical can-
cer (OR=3.047; 95% CI: 1.788-5.192, P=0.000), heterozy-
gostiy for the CGC haplotype had no effect on risk of
cervical cancer (P = 0.321). Heterozygosity for the CGT
haplotype was more common among patients, suggest-
ing an increased risk of cervical cancer among CGT he-
terozygotes (OR = 1.846; 95% CI: 1.156 - 2.945, P =
0.010). Homozygosity for the CGT haplotype was not
statistically significantly different among groups, possibly
because of the small sample size (P=0.338). The fre-
quency of the CCC haplotype was not statisticallyTable 4 Haplotypes of the three p21 SNPs (rs1801270,
rs3176352, and rs1059234) in patients and controls
Haplotype Case (n=393) Control (n=434)
ht Haplotype Percentage (%)(95% CI) Percentage (%)(95% CI)
1 AGT 37.88 (37.68-38.07) 44.42 (44.18-44.65)
2 CCC 29.30 (29.03-29.57) 33.11 (32.85-33.36)
3 CGC 20.92 (20.69-21.15) 11.63 (11.41-11.86)
4 CGT 7.07 (6.88-7.26) 3.91 (3.71-4.11)
5 AGC 2.20 (2.05-2.36) 3.52 (3.40-3.63)
Haplotypes with overall estimated frequency < 3% are not shown.significantly different among the two groups and was
therefore not associated with risk of cervical cancer in
this population.
Discussion
This study looked for an association between five p21
SNPs (rs1801270, rs762623, rs2395655, rs3176352,
rs1059234) and the risk of cervical cancer in a Chinese
population. Studies have suggested an association be-
tween the p21 codon 31 polymorphism (rs1801270) and
susceptibility to cancer, but with conflicting results
[17,20,23,24]. Roh [17], Lee [23] and Jiang [24] found A−/− 184 (46.8) 183 (42.2) reference
ht3-CGC
ht3/ht3 51 (13.0) 21 (4.8) 3.047 (1.788-5.192) 0.000
ht3/- 59 (15.0) 56 (12.9) 1.322 (0.888-1.970) 0.169
−/− 283 (72.0) 357 (82.3) reference
ht4- CGT
ht4/ht4 3(0.8) 1(0.2) 3.054 (0.311-29.936) 0.338
ht4/- 50 (12.7) 32 (7.4) 1.846 (1.156-2.945) 0.010
−/− 340 (86.5) 401 (92.4) reference
* P value was adjusted for age and smoking by multiple logistic regressions.
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Bhattacharya [20] and Tian [25] demonstrated C allele
seem to be the risk factor. We found that the rs1801270
AA genotype and A allele occur more frequently in
cancer-free controls, and seem to have a significant pro-
tective effect in Chinese women. Our results with the
rs1801270 SNP are consistant with some previous
reports [20,25], but differ from others [17,19,23,26],
which found a deleterious effect of the rs1801270 A al-
lele in cervical cancer. This discrepancy could be due to
ethnic differences or sample size. Further, large-scale
studies will be needed to validate the role of the p21
codon 31 SNP in cervical cancer.
Of the five p21 SNPs studied, three (rs1801270,
rs3176352, and rs1059234) were found to be in linkage
disequilibrium (LD). Haplotype analysis of these three
p21 SNPs showed that haplotype AGT (which includes
the rs1801270 A allele) occurs less frequently in cervical
cancer patients than in controls. Our results suggest that
both homozygosity and heterozygosity of the haplotype
AGT may reduce the risk of cervical cancer in Chinese
women. However, the heterozygosity of the haplotype
CGT increases the risk of cervical cancer. In the current
study, we found the association of the other two loci
(rs3176352 and rs1059234) and cervical cancer tended
to statistical significance. However, the role of the two
p21 polymorphisms needs to be studied in a larger cer-
vical cancer patient cohort in the future.
The molecular mechanism underlying the protective
effect of the rs1801270 A allele in cervical cancer is un-
clear. This C/A SNP within the p21 codon 31 results in
a substitution of arginine for serine in a conserved re-
gion of the protein and may affect the DNA binding af-
finity and thus physiological function of p21 [27]. The
p21 protein plays a role in cell cycle regulation. It binds
to cyclin-CDK complexes to arrest cell cycle progression
at G1 phase. The transcription of p21 is partially regulated
by p53, which binds to the p21 promoter and induces ex-
pression of p21. Therefore, functional domains as well as
the promoter region of p21 could be affected by SNPs and
lead to altered p21 functionality [26]. The rs2395655 SNP
is located in the transcription factor E2F binding region.
The rs1059234 SNP occurs in the 3’-non coding region
and may affect p21 mRNA stability. Although our results
do not find an association between these SNPs and cer-
vical cancer, the molecular mechanism(s) through which
p21 SNPs affect risk of cervical cancer is a field that
should be pursued further.
Studies of p21 expression in cervical cancer have
reported higher levels of expression of p21 in cancer tis-
sue compared to normal tissue [28,29], while others
showed there is no association between the expression
of p21 and the pathological features of cervical cancer
[30]. After infection with HPV, the E6 protein of HPVpromotes p53 degradation and thus inhibits p21 expres-
sion and function. Loss of p21 results in decreased abi-
lity of the cell to stop cell cycle progression, possibly
leading to carcinogenesis. However, the molecular
mechanisms that mediate carcinogenesis are very com-
plex, and this is not the only plausible explanation of the
relationship between p21, p53, HPV, and cancer.
Conclusion
In conclusion, our study showed a significant association
between the A allele of the p21 rs1801270 SNP and
decreased risk of cervical cancer in a Chinese popula-
tion. Furthermore, a haplotype containing the rs1801270
A allele was also associated with decreased risk of cervical
cancer in this population. The molecular mechanisms
underlying this association remain to be determined.
Additional files
Additional file 1: Table S1. Methods used for p21 SNP genotyping.
Additional file 2: Figure S1. Sample sequence tracing of rs762623 and
rs2395655 SNPs showing homozygosity for each allele (top and bottom)
or heterozygosity (middle).
Additional file 3: Figure S2. PCR-RFLP analysis of p21 SNP rs1801270A/
C. The 310 bp PCR products were digested by BglI, and presence of the
C allele resulted in two bands of sizes 239 and 71 bp. Electrophoresis was
performed in 3% agarose gel.
Additional file 4: Figure 3. PCR-RFLP analysis of p21 SNP rs3176352A/
C. The 448 bp PCR products were digested by ApaLI, and presence of the
C allele resulted in two bands of sizes 289 and 159 bp. Electrophoresis
was performed in 2.5% agarose gel.
Additional file 5: Figure S4. PCR-RFLP analysis of p21 SNP rs1059234T/
C. The 480 bp PCR products were digested by PstI, and presence of the C
allele resulted in two bands of sizes 291 and 189 bp. Electrophoresis was
performed in 2.5% agarose gel.
Additional file 6: Table S2. Pairwise linkage disequilibrium analysis for
all five p21 SNPs for all subjects studied.
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